Challenges And Opportunities In Overcoming EGFR TKI Resistance In NSCLC

in mrmed •  10 months ago 

Non-small cell lung cancer is a slower-growing variant that can be managed through various approaches, such as radiation therapy, surgery, chemotherapy, and targeted therapy. The tyrosine kinase inhibitors (TKIs) resistance of the epidermal growth factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) has a therapeutic challenge.

mrmed mrmedpharmacy egfrmutations lungcancer nsclc tagrisso80
10 months ago by

Downvoting a post can decrease pending rewards and make it less visible. Common reasons:

  • Disagreement on rewards
  • Fraud or plagiarism
  • Hate speech or trolling
  • Miscategorized content or spam

Submit
$0.00
    0
    Authors get paid when people like you upvote their post.
    If you enjoyed what you read here, create your account today and start earning FREE STEEM!